Quality of Life and Nutritional Improvements in Cirrhotic Patients

Exclusion Criteria

• •Active alcohol consumption
• •Serum total bilirubin level \> 5 mg/dl
• •History of hepatocellular carcinoma (HCC) and malignancies other than basal cell carcinoma of the skin
• •Pregnant or breastfeeding women
• •Subject has renal insufficiency requiring routine dialysis
• •Poorly controlled diabetes as defined by HgA1C \> 10
• •Narcotic/psychotropic usage other than a stable dose of antidepressant and/or methadone. Neurontin (gabapentin) and Lyrica (pregabalin) are permitted if the subject has been on a stable dose for at least 2 months prior to the screening visit and no change of dosing is expected throughout the length of the trial
• •Any of the following diagnoses:
• •HIV
• •Evidence of severe concomitant illness or any condition that makes them unsuitable for the study in the opinion of the investigator(s)
• •Subject has received an investigational drug within 30 days prior to enrollment